HomeNewsWorld NewsBausch + Lomb’s New CEO Inks First Big Deal
Eye-care company has agreed to pay $1.75 billion for Novartis’s dry-eye treatment Xiidra.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.